Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France

• Autors principals: Amy Lee (Autor), Benjamin Davido (Autor), Ekkehard Beck (Autor), Clarisse Demont (Autor), Keya Joshi (Autor), Michele Kohli (Autor), Michael Maschio (Autor), Mathieu Uhart (Autor), Nadia El Mouaddin (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 variant-adapted vaccines in Fall 2023 and Spring 2024 in France. The number of symptomatic SAR...